A Phase 1, Open Label, Multicenter, Dose Escalating Cohort Study to Evaluate the Safety and Tolerability of Daily Oral Administration of P2745 in Patients with Relapsed/Refractory Hematologic Malignancies

Trial Profile

A Phase 1, Open Label, Multicenter, Dose Escalating Cohort Study to Evaluate the Safety and Tolerability of Daily Oral Administration of P2745 in Patients with Relapsed/Refractory Hematologic Malignancies

Discontinued
Phase of Trial: Phase I

Latest Information Update: 30 Aug 2016

At a glance

  • Drugs P 2745 (Primary)
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Sponsors Piramal Phytocare
  • Most Recent Events

    • 23 May 2013 Status changed from recruiting to discontinued as reported by Clinical Trials Registry - India.
    • 30 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top